Immune Targeting Systems Ltd.

Immune Targeting Systems is developing synthetic vaccines that target rapidly mutating viruses. Its lead product is a universal vaccine designed to target all potential seasonal and pandemic flu strains, including H1N1 and avian H5N1. Since ITS uses synthetic sequences, it does not have to rely on chicken eggs for production, thus eliminating a key bottleneck in conventional flu vaccine production.